Skip to main content
SpringerLink
Log in

Consider pharmacological treatment to close patent ductus arteriosus in preterm infants when the condition is haematologically significant

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The management of patent ductus arteriosus (PDA) in preterm infants may take a conservative, pharmacological and/or surgical approach. Pharmacological treatment to close the ductus may be indicated in symptomatic preterm infants with haematologically significant PDA. Indomethacin and ibuprofen (the only approved agents for PDA in the USA) appear to have similar efficacy in this indication; however, ibuprofen generally has a better tolerability profile. Paracetamol (acetaminophen) is becoming increasingly used, despite a lack of clinical data. Surgery is an option in infants with refractory PDA or contraindications to drug therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010;125(5):1020–30.

    Article  PubMed  Google Scholar 

  2. Sivanandan S, Agarwal R. Pharmacological closure of patent ductus arteriosus: selecting the agent and route of administration. Pediatr Drugs. 2016;18(2):123–38.

    Article  Google Scholar 

  3. Kaempf JW, Wu YX, Kaempf AJ, et al. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants? J Perinatol. 2012;32(5):344–8.

    Article  CAS  PubMed  Google Scholar 

  4. Kluckow M, Jeffery M, Gill A, et al. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2014;99(2):F99–104.

    Article  PubMed  Google Scholar 

  5. Cooke L, Steer P, Woodgate P. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2003;(2):CD003745.

  6. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2010;(7):CD000174.

  7. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2015;(2):CD003481.

  8. Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2007;(2):CD003480.

  9. Van Overmeire B, Van de Broek H, Van Laer P, et al. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr. 2001;138(2):205–11.

    Article  PubMed  Google Scholar 

  10. Görk AS, Ehrenkranz RA, Bracken MB. Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants. Cochrane Database Syst Rev. 2008;(1):CD006071.

  11. Gouyon JB, Kibleur Y. Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants. Clin Ther. 2010;32(10):1740–8.

    Article  CAS  PubMed  Google Scholar 

  12. Erdeve O, Sarici SU, Sari E, et al. Oral-ibuprofen-induced acute renal failure in a preterm infant. Pediatr Nephrol. 2008;23(9):1565–7.

    Article  PubMed  Google Scholar 

  13. Ment LR, Vohr BR, Makuch RW, et al. Prevention of intraventricular hemorrhage by indomethacin in male preterm infants. J Pediatr. 2004;145(6):832–4.

    Article  CAS  PubMed  Google Scholar 

  14. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001;344(26):1966–72.

    Article  CAS  PubMed  Google Scholar 

  15. Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther. 2005;30(2):121–32.

    Article  CAS  PubMed  Google Scholar 

  16. Dani C, Vangi V, Bertini G, et al. High-dose ibuprofen for patent ductus arteriosus in extremely preterm infants: a randomized controlled study. Clin Pharmacol Ther. 2012;91(4):590–6.

    Article  CAS  PubMed  Google Scholar 

  17. Sosenko IR, Fajardo MF, Claure N, et al. Timing of patent ductus arteriosus treatment and respiratory outcome in premature infants: a double-blind randomized controlled trial. J Pediatr. 2012;160(6):929–35.e1.

    Article  Google Scholar 

  18. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants. Cochrane Database Syst Rev. 2015;(3):CD010061.

  19. Weisz DE, More K, McNamara PJ, et al. PDA ligation and health outcomes: a meta-analysis. Pediatrics. 2014;133(4):e1024–46.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Pediatric Drugs 2016;18(2):123–38 [2] by salaried/contracted employees of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Consider pharmacological treatment to close patent ductus arteriosus in preterm infants when the condition is haematologically significant. Drugs Ther Perspect 33, 22–25 (2017). https://doi.org/10.1007/s40267-016-0329-y

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-016-0329-y

    Search

    Navigation